Editorials
Establishment of a malignant pleural effusion mouse model: pathogenesis pathways
Translational Lung Cancer Research
2012;
1
(3)
:163-166
.
(27 September 2012)
Malignant pleural effusion: further translational research is crucial
Translational Lung Cancer Research
2012;
1
(3)
:167-169
.
(27 September 2012)
Original Article
Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein
Translational Lung Cancer Research
2012;
1
(3)
:170-178
.
(27 September 2012)
Review Articles
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Translational Lung Cancer Research
2012;
1
(3)
:179-193
.
(27 September 2012)
MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications
Translational Lung Cancer Research
2012;
1
(3)
:194-207
.
(27 September 2012)
Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a concise review
Translational Lung Cancer Research
2012;
1
(3)
:208-213
.
(27 September 2012)
Perspectives
Combined treatment with MET inhibitors and other therapies in lung cancer
Translational Lung Cancer Research
2012;
1
(3)
:214-218
.
(27 September 2012)
First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Translational Lung Cancer Research
2012;
1
(3)
:219-223
.
(27 September 2012)
Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC
Translational Lung Cancer Research
2012;
1
(3)
:224-226
.
(27 September 2012)
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study
Translational Lung Cancer Research
2012;
1
(3)
:227-229
.
(27 September 2012)
